$0.36
-0.04 (-9.25%)
Open$0.38
Previous Close$0.40
Day High$0.39
Day Low$0.30
52W High$14.71
52W Low$0.36
Volume—
Avg Volume1.77M
Market Cap4.72M
P/E Ratio—
EPS$-24.74
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+5,785.8% upside
Current
$0.36
$0.36
Target
$21.13
$21.13
$13.63
$21.13 avg
$23.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.00M | 1.99M | 1.61M |
| Net Income | -74,230 | -69,635 | -62,110 |
| Profit Margin | -3.7% | -3.5% | -3.9% |
| EBITDA | -116,342 | -139,946 | -107,891 |
| Free Cash Flow | -67,743 | -57,560 | -72,298 |
| Rev Growth | +11.8% | +24.3% | -3.3% |
| Debt/Equity | 0.69 | 0.66 | 0.82 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |